587 related articles for article (PubMed ID: 29891538)
1. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1
D'Angelo SP; Melchiori L; Merchant MS; Bernstein D; Glod J; Kaplan R; Grupp S; Tap WD; Chagin K; Binder GK; Basu S; Lowther DE; Wang R; Bath N; Tipping A; Betts G; Ramachandran I; Navenot JM; Zhang H; Wells DK; Van Winkle E; Kari G; Trivedi T; Holdich T; Pandite L; Amado R; Mackall CL
Cancer Discov; 2018 Aug; 8(8):944-957. PubMed ID: 29891538
[TBL] [Abstract][Full Text] [Related]
2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
3. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
[TBL] [Abstract][Full Text] [Related]
4. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
5. Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!
Keung EZ; Tawbi HA
Cancer Discov; 2018 Aug; 8(8):914-917. PubMed ID: 30076141
[No Abstract] [Full Text] [Related]
6. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
[TBL] [Abstract][Full Text] [Related]
7. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
[TBL] [Abstract][Full Text] [Related]
8. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
[TBL] [Abstract][Full Text] [Related]
10. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.
Nowicki TS; Berent-Maoz B; Cheung-Lau G; Huang RR; Wang X; Tsoi J; Kaplan-Lefko P; Cabrera P; Tran J; Pang J; Macabali M; Garcilazo IP; Carretero IB; Kalbasi A; Cochran AJ; Grasso CS; Hu-Lieskovan S; Chmielowski B; Comin-Anduix B; Singh A; Ribas A
Clin Cancer Res; 2019 Apr; 25(7):2096-2108. PubMed ID: 30573690
[TBL] [Abstract][Full Text] [Related]
11. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
13. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
[TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Rapoport AP; Stadtmauer EA; Binder-Scholl GK; Goloubeva O; Vogl DT; Lacey SF; Badros AZ; Garfall A; Weiss B; Finklestein J; Kulikovskaya I; Sinha SK; Kronsberg S; Gupta M; Bond S; Melchiori L; Brewer JE; Bennett AD; Gerry AB; Pumphrey NJ; Williams D; Tayton-Martin HK; Ribeiro L; Holdich T; Yanovich S; Hardy N; Yared J; Kerr N; Philip S; Westphal S; Siegel DL; Levine BL; Jakobsen BK; Kalos M; June CH
Nat Med; 2015 Aug; 21(8):914-921. PubMed ID: 26193344
[TBL] [Abstract][Full Text] [Related]
15. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
16. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H; Takada K; Emori M; Kakunaga S; Endo M; Matsumoto Y; Sasada T; Sato E; Yamada T; Matsumine A; Nagata Y; Watanabe T; Kageyama S; Shiku H
Int J Cancer; 2023 Jun; 152(12):2554-2566. PubMed ID: 36727538
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
[TBL] [Abstract][Full Text] [Related]
19. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA
J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407
[TBL] [Abstract][Full Text] [Related]
20. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
